Address: Lage Mosten 33, 4822 NK, Noord-Brabant,Netherlands
Tel: +31-765731140
Web: http://www.ucbpharma.nl/home
As a global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of € 3.1 billion in 2009, UCB aspires to be the patient-centric global biopharmaceutical leader transforming the lives of people living with severe diseases.
By integrating biology (bio) and chemistry (pharma), we can gain much deeper insights into disease pathways, including the complexities of severe diseases, as well as producing more potent, cost-effective drugs.
The unique combination of expertise in large, antibody-based molecules and small, chemically-derived molecules places us in a strong position to realise this ambition. Cimzia®, our New Biological Entity (NBE), targeted at Crohn’s disease and rheumatoid arthritis, is one of the first fruits of this synergy of biology and chemistry.
UCB’s medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Vimpat® (lacosamide): Epilepsy
Keppra® (levetiracetam): Epilepsy
Neupro® (rotigotine): Parkinson’s disease, Restless Legs Syndrome
Nootropil® (piracetam): Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII): Attention Deficit Hyperactivity Disorder (ADHD)
Cimzia® (certolizumab pegol): Crohn’s disease, Rheumatoid arthritis
Xyzal® (levocetirizine): Allergies
Zyrtec® (cetirizine):Allergies
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII): Respiratory disease
Floris Van Haselen, Business Development Director Europe for O&M Movianto, one of the rare logistics companies to be fully specialized and to only operate in the healthcare sector, explains how the company…
Peter Schoevers, CEO and co-founder of Julius Clinical, explains how this innovative and thriving organization allies the academic strength of an ARO with the business-oriented leadership of a CRO. Julius…
Isabelle de Walsche, Managing Director of Gedeon Richter Benelux, provides us with an update on the development of this striving and ambitious player in the women’s healthcare field and shares…
Roeland Van Dam, CEO of Bilthoven Biologicals, a historical Dutch company which remains at the forefront of vaccine production, explains how being integrated into the Serum Institute of India has…
Rob de Roock, Director CL Healthcare for UPS Europe, gives us a brief outline of the current market dynamics impacting the booming European healthcare logistics industry and explains how UPS…
Han Brouwer, General Manager for Actelion in the Netherlands, explains how Opsumit’s successful market launch has strengthened Actelion’s leadership position in the pulmonary arterial hypertension (PAH) field. He calls for…
Bart van de Kerkhof highlights how Covidien’s acquisition will drive Medtronic to new heights thanks to a broader product portfolio. Medtronic is already piloting projects and cooperating with key stakeholders to…
Anita Atema, General Manager of Celgene, reveals Celgene’s inspiring and concrete initiatives that illustrate how a true willingness to cooperate with healthcare stakeholders and a remarkable effort of transparency can help…
Amgen Netherlands is preparing to launch five new products next year, including their leading cardiovascular biotech product Repatha and recently announced the acquisition of the Dutch biotech Dezima. General manager…
Maikel Beerens, CEO and founder of Xilloc, a promising Dutch company that designs patient-specific implants, anatomical models and surgical guides for bone reconstruction or augmentation with the help of 3-D…
Michiel van der Veen, CEO of GenKey, a global player in biometric identity management based in Eindhoven, explains how both the healthcare industry and public health schemes could benefit from…
Menno Kok and Roel Kamerling, Director and CIO of Medical Delta, a life sciences, health & technology innovation cluster around Leiden, Delft and Rotterdam in the West of the Netherlands,…
See our Cookie Privacy Policy Here
